# S3A Guidance: Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies: Focus on Microsampling - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/s3a-guidance-note-for-guidance-on-toxicokinetics-the-assessment-of-systemic-exposure-in-toxicity-studies-focus-on-microsampling/9ffd98db-d7b4-4ab7-a1b8-146abe8b400e

> FDA guidance document: S3A Guidance: Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies: Focus on Microsampling. Issue date: May 09, 2018. Get complete insights and analysis.

---

## Details

- Title: S3A Guidance: Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies: Focus on Microsampling
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2018-05-09
- Last Changed: 2020-04-17
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2016-D-2513">FDA-2016-D-2513</a>

## Related Documents

- [Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients Questions and Answers Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/q7-good-manufacturing-practice-guidance-for-active-pharmaceutical-ingredients-questions-and-answers-guidance-for-industry/1600b7d2-35c2-41f8-add1-35f8c98ddb9b)
- [Q11 Development and Manufacture of Drug Substances--Questions and Answers (Chemical Entities and Biotechnological/Biological Entities)](https://www.globalkeysolutions.net/guidances/guidance-document/q11-development-and-manufacture-of-drug-substances-questions-and-answers-chemical-entities-and-biotechnologicalbiological-entities/4bdf3485-1128-4a4c-bfdf-7ed5513ad725)
- [S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers](https://www.globalkeysolutions.net/guidances/guidance-document/s9-nonclinical-evaluation-for-anticancer-pharmaceuticals-questions-and-answers/5b838cf4-2c2e-4c10-8a24-439ce4ce61f1)